Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 63Neoplasms 59Leukemia, Myeloid, Acute 59Multiple Myeloma 53Colorectal Neoplasms 48Lymphoma 46Recurrence 45Carcinoma, Hepatocellular 45Stomach Neoplasms 43Pancreatic Neoplasms 40Neoplasm Metastasis 39Prostatic Neoplasms 34Melanoma 34Leukemia 30Lymphoma, Non-Hodgkin 27Lymphoma, B-Cell 27Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 24Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 21Esophageal Neoplasms 21Carcinoma, Renal Cell 20Myelodysplastic Syndromes 19Leukemia, Lymphocytic, Chronic, B-Cell 19Hematologic Neoplasms 19Colonic Neoplasms 19Head and Neck Neoplasms 18Lymphoma, Mantle-Cell 17

Interventions

camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Colorectal Cancer Recurrent × Clear all
NCT04067986 2020-09-29

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Zhongshan Hospital Xiamen University

Phase 1/2 Unknown
62 enrolled
Gastrointestinal

Colorectal Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡